← Leaderboards
Terrence F Blaschke
Stanford University
$1,576,818
Attributed
$1,576,818
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $381.8K · FY2005–07$500K$375K$250K$125K$0
'05
'06
'07
Funding mix
By agency
NIH$1,576,818 · 4
By mechanism
R01$1,089,308 · 1
T32$352,232 · 1
M01$135,278 · 2
Top collaborators
No co-investigators on record.
Most similar at Stanford University
Same institution · by research overlap
- Branimir I Sikic$8,041,001
- Thomas C Merigan$8,107,440
- Gary K Schoolnik$16,579,521
- Melissa L Bondy$46,044,245
- Peter Rudd$1,985,482
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchRitonavirPharmacokineticsSaquinavirDrug InteractionsAntihypercholesterolemic AgentHyperlipidemiaHuman Therapy EvaluationBlood Disorder ChemotherapyAntiaids AgentMetabolism Disorder ChemotherapyDrug Screening /EvaluationDrug ExposureDoseDosageBrazilDesignHigh Performance Liquid ChromatographyHepatotoxicityHigh PrevalenceDailyEfavirenzCondition
Grant awards (9)
Optimizing NNRTI Doses in Patients with HIV and TB$348,551
R01 · FY2007 · AI · contact PI
Optimizing NNRTI Doses in Patients with HIV and TB$358,961
R01 · FY2006 · AI · contact PI
Optimizing NNRTI Doses in Patients with HIV and TB$381,796
R01 · FY2005 · AI
Pharmacogenomics of ADRs: Calcineurin Inhibitor Toxicity$179,142
T32 · FY2003 · GM
TRAINING PROGRAM IN CLINICAL PHARMACOLOGY$173,090
T32 · FY2002 · GM
INTERACTIONS BETWEEN PROTEASE INHIBITORS/ LIPID LOWERING$134,676
M01 · FY2001 · RR
INTERACTIONS BETWEEN PROTEASE INHIBITORS/ LIPID LOWERING$0
M01 · FY2001 · RR
TEST EFFECT OF EFFECT OF NFV, RTV &SOFT GEL SQV$602
M01 · FY2000 · RR
INTERACTIONS BETWEEN PROTEASE INHIBITORS/ LIPID LOWERING$0
M01 · FY2000 · RR